Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Abivax (France)
h-index: 17
Total citations: 758
Total papers: 63
Homepage:
http://www.abivax.com/en/
Recent papers from Abivax (France)
Advanced Therapy Treatment Patterns in Moderate-to-Severe Ulcerative Colitis: A Long-Term Retrospective Claims Analysis
Crohn s & Colitis 360 · 2026
DOP101Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0804Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active ulcerative colitis: results from the two Phase 3 placebo-controlled ABTECT induction trials
Journal of Crohn s and Colitis · 2026
P0712Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials
Journal of Crohn s and Colitis · 2026
P0892Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results in subgroups including or excluding patients with prior JAK-IR from ABTECT Phase 3 induction trials
Journal of Crohn s and Colitis · 2026
DOP057Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0952Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the two Phase 3 ABTECT induction trials
Journal of Crohn s and Colitis · 2026
DOP102Improvements in patient-reported fatigue among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0694Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P1159Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0928Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0923Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0922Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0713Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0690Impact of concomitant use of corticosteroids on efficacy and safety of obefazimod at week 8 of induction trials in patients with moderately to severely active ulcerative colitis: results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P0894Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled analysis of ABTECT Phase 3 induction trials
Journal of Crohn s and Colitis · 2026
DOP060Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 phase 3 trials
Journal of Crohn s and Colitis · 2026
P1048Impact of age of subjects on the efficacy and safety of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials
Journal of Crohn s and Colitis · 2026
P1077Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials
Journal of Crohn s and Colitis · 2026
OP30Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease
Journal of Crohn s and Colitis · 2026